FDA Approves Briumvi to Treat Relapsing Multiple Sclerosis
On December 28, 2022, the U.S. Food and Drug Administration (FDA) approved Briumvi (ublituximab), a disease-modifying therapy (DMT) to treat relapsing forms of multiple sclerosis (RMS) in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS. An estimated one million people in the United States live with MS, with about 25,000 new people diagnosed each year, according to the National MS Society.
FDA Approves Briumvi to Treat Relapsing Multiple Sclerosis
On December 28, 2022, the U.S. Food and Drug Administration (FDA) approved Briumvi (ublituximab), a disease-modifying therapy (DMT) to treat relapsing forms of multiple sclerosis (RMS) in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS. An estimated one million people in the United States live with MS, with about 25,000 new people diagnosed each year, according to the National MS Society.
BY مرکز تحقیقات زیست فناوری دانشگاه علوم پزشکی تهران
The imprisonment came as Telegram said it was "surprised" by claims that privacy commissioner Ada Chung Lai-ling is seeking to block the messaging app due to doxxing content targeting police and politicians. Those being doxxed include outgoing Chief Executive Carrie Lam Cheng Yuet-ngor, Chung and police assistant commissioner Joe Chan Tung, who heads police's cyber security and technology crime bureau. During a meeting with the president of the Supreme Electoral Court (TSE) on June 6, Telegram's Vice President Ilya Perekopsky announced the initiatives. According to the executive, Brazil is the first country in the world where Telegram is introducing the features, which could be expanded to other countries facing threats to democracy through the dissemination of false content. Write your hashtags in the language of your target audience. A Hong Kong protester with a petrol bomb. File photo: Dylan Hollingsworth/HKFP.
from us
